{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T15:39:22Z","timestamp":1771947562016,"version":"3.50.1"},"reference-count":282,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100020582","name":"National Institute of Pharmaceutical Education and Research, Raebareli","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020582","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.lfs.2024.122806","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T19:28:25Z","timestamp":1717788505000},"page":"122806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Unravelling the complexities of non-alcoholic steatohepatitis: The role of metabolism, transporters, and herb-drug interactions"],"prefix":"10.1016","volume":"351","author":[{"given":"Ravi Adinarayan","family":"Somabattini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahla","family":"Sherin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhukya","family":"Siva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neelanjan","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satheesh Kumar","family":"Nanjappan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl","key":"10.1016\/j.lfs.2024.122806_bb0005","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0010","first-page":"71","article-title":"Diversity in NAFLD: a review of manifestations of nonalcoholic fatty liver disease in different ethnicities globally","volume":"9","author":"Han","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.lfs.2024.122806_bb0015","doi-asserted-by":"crossref","unstructured":"A. A. f. t. S. o. L. Diseases, L. A. A. f. t. S. o. t. Liver, E. A. f. t. S. o. t. Liver, A call for unity: the path towards a more precise and patient-centric nomenclature for NAFLD, Hepatology, 78, (1), (2023), 3\u20135, doi:https:\/\/doi.org\/10.1097\/hep.0000000000000412.","DOI":"10.1097\/HEP.0000000000000412"},{"issue":"4","key":"10.1016\/j.lfs.2024.122806_bb0020","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3350\/cmh.2020.0163","article-title":"The effect of moderate alcohol drinking in nonalcoholic fatty liver disease","volume":"26","author":"Choi","year":"2020","journal-title":"Clin. Mol. Hepatol."},{"issue":"4","key":"10.1016\/j.lfs.2024.122806_bb0025","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/cld.710","article-title":"The epidemiology of nonalcoholic steatohepatitis","volume":"11","author":"Younossi","year":"2018","journal-title":"Clin. Liver Dis."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0030","doi-asserted-by":"crossref","first-page":"8107","DOI":"10.1038\/s41598-019-44563-y","article-title":"Effects of a\u00e7ai on oxidative stress, ER stress, and inflammation-related parameters in mice with high fat diet-fed induced NAFLD","volume":"9","author":"de Freitas Carvalho","year":"2019","journal-title":"Sci. Rep."},{"issue":"7675","key":"10.1016\/j.lfs.2024.122806_bb0035","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1038\/550S101a","article-title":"Fatty liver disease: turning the tide","volume":"550","author":"Drew","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.lfs.2024.122806_bb0045","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1007\/s10620-016-4143-0","article-title":"Global epidemiology of nonalcoholic fatty liver disease and perspectives on US minority populations","volume":"61","author":"Sherif","year":"2016","journal-title":"Dig. Dis. Sci."},{"issue":"12","key":"10.1016\/j.lfs.2024.122806_bb0050","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.2337\/db10-0224","article-title":"Adipose tissue dysfunction signals progression of hepatic steatosis towards nonalcoholic steatohepatitis in C57BL\/6 mice","volume":"59","author":"Duval","year":"2010","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0055","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/gut.2003.024935","article-title":"Cytokines and the pathogenesis of non-alcoholic steatohepatitis","volume":"54","author":"Diehl","year":"2005","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0060","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1210\/en.2015-1866","article-title":"Hepatocyte-specific disruption of CD36 attenuates fatty liver and improves insulin sensitivity in HFD-fed mice","volume":"157","author":"Wilson","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.lfs.2024.122806_bb0065","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3389\/fmed.2020.00450","article-title":"Intrahepatic expression of fatty acid translocase CD36 is increased in obstructive sleep apnea","volume":"7","author":"Rey","year":"2020","journal-title":"Front. Med."},{"issue":"18","key":"10.1016\/j.lfs.2024.122806_bb0070","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.lfs.2024.122806_bb0075","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2010.01275.x","article-title":"Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c","volume":"12","author":"Ferr\u00e9","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.lfs.2024.122806_bb0080","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.coph.2021.07.021","article-title":"A double-edged sword: the Kelch-like ECH-associated protein 1-nuclear factor erythroid-derived 2-related factor 2-antioxidant response element pathway targeted pharmacological modulation in nonalcoholic fatty liver disease","volume":"60","author":"Wang","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"issue":"4","key":"10.1016\/j.lfs.2024.122806_bb0085","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.lfs.2024.122806_bb0090","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0095","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1530\/EC-20-0490","article-title":"Pathophysiology of NASH in endocrine diseases","volume":"10","author":"Gariani","year":"2021","journal-title":"Endocr. Connect."},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0100","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/qjmed\/hcp158","article-title":"Pathogenesis of non-alcoholic fatty liver disease","volume":"103","author":"Dowman","year":"2010","journal-title":"Qjm"},{"issue":"4","key":"10.1016\/j.lfs.2024.122806_bb0105","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1055\/s-0028-1091981","article-title":"Mechanisms of disease progression in nonalcoholic fatty liver disease","volume":"28","author":"Jou","year":"2008","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.lfs.2024.122806_bb0110","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/648308","article-title":"Herbal medicines for the treatment of nonalcoholic steatohepatitis: current scenario and future prospects","volume":"2014","author":"Jadeja","year":"2014","journal-title":"Evid. Based Complement. Alternat. Med."},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbj.0000000000000015","article-title":"Understanding the relevance of herb-drug interaction studies with special focus on interplays: a prerequisite for integrative medicine","volume":"4","author":"Borse","year":"2019","journal-title":"Porto Biomed. J."},{"issue":"8","key":"10.1016\/j.lfs.2024.122806_bb0120","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/jpp\/rgac022","article-title":"Investigation of the effect of acai berry on the pharmacokinetics of atorvastatin, alogliptin and empagliflozin: a herb\u2013drug interaction study","volume":"74","author":"Nanjappan","year":"2022","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.lfs.2024.122806_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.603926","article-title":"Non-alcoholic steatohepatitis: a review of its mechanism, models and medical treatments","volume":"11","author":"Peng","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0130","first-page":"9","article-title":"Non alcoholic fatty liver disease and metabolic syndrome","volume":"13","author":"Paschos","year":"2009","journal-title":"Hippokratia"},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0135","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5009\/gnl.2012.6.2.149","article-title":"NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications","volume":"6","author":"Farrell","year":"2012","journal-title":"Gut Liver"},{"issue":"12","key":"10.1016\/j.lfs.2024.122806_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/cells11121883","article-title":"Neutrophils actively contribute to obesity-associated inflammation and pathological complications","volume":"11","author":"Uribe-Querol","year":"2022","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.lfs.2024.122806_bb0145","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1631\/jzus.B2101075","article-title":"Roles of neutrophil reactive oxygen species (ROS) generation in organ function impairment in sepsis","volume":"23","author":"Lu","year":"2022","journal-title":"J Zhejiang Univ Sci B"},{"key":"10.1016\/j.lfs.2024.122806_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.997018","article-title":"Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications","volume":"12","author":"Fang","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.lfs.2024.122806_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.701511","article-title":"Gut microbiota and their role in health and metabolic disease of dairy cow","volume":"8","author":"Xu","year":"2021","journal-title":"Front. Nutr."},{"issue":"12","key":"10.1016\/j.lfs.2024.122806_bb0160","article-title":"Molecular mechanisms that link oxidative stress, inflammation, and fibrosis in the liver","volume":"9","author":"Ramos-Tovar","year":"2020","journal-title":"Antioxidants (Basel)"},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/metabo13030322","article-title":"Hepatic mitochondria-gut microbiota interactions in metabolism-associated fatty liver disease","volume":"13","author":"Bellanti","year":"2023","journal-title":"Metabolites"},{"issue":"22","key":"10.1016\/j.lfs.2024.122806_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232213675","article-title":"Microbiota dysbiosis and gut barrier dysfunction associated with non-alcoholic fatty liver disease are modulated by a specific metabolic cofactors\u2019 combination","volume":"23","author":"Quesada-V\u00e1zquez","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0175","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2024.122806_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.603926","article-title":"Non-alcoholic steatohepatitis: a review of its mechanism, models and medical treatments","volume":"11","author":"Peng","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.lfs.2024.122806_bb0185","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.metabol.2015.11.008","article-title":"Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"65","author":"Brown","year":"2016","journal-title":"Metabolism"},{"issue":"42","key":"10.1016\/j.lfs.2024.122806_bb0190","doi-asserted-by":"crossref","first-page":"15539","DOI":"10.3748\/wjg.v20.i42.15539","article-title":"Histopathology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Takahashi","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.lfs.2024.122806_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.597583","article-title":"Pathophysiology of NAFLD and NASH in experimental models: the role of food intake regulating peptides","volume":"11","author":"Ko\u0159\u00ednkov\u00e1","year":"2020","journal-title":"Front. Endocrinol."},{"issue":"5","key":"10.1016\/j.lfs.2024.122806_bb0200","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1159\/000501851","article-title":"Rodent models of nonalcoholic fatty liver disease","volume":"101","author":"Zhong","year":"2020","journal-title":"Digestion"},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0205","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jhep.2017.10.031","article-title":"Preclinical models of non-alcoholic fatty liver disease","volume":"68","author":"Santhekadur","year":"2018","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.lfs.2024.122806_bb0210","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/liv.12335","article-title":"Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype","volume":"34","author":"Farrell","year":"2014","journal-title":"Liver Int."},{"issue":"5","key":"10.1016\/j.lfs.2024.122806_bb0215","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1872-034X.2012.01101.x","article-title":"Fatty liver Shionogi-ob\/ob mouse: a new candidate for a non-alcoholic steatohepatitis model","volume":"43","author":"Sugihara","year":"2013","journal-title":"Hepatol. Res."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0220","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47737-w","article-title":"The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids","volume":"9","author":"Prill","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0225","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91187-2","article-title":"Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD\/NASH","volume":"11","author":"Escutia-Guti\u00e9rrez","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0230","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/path.4829","article-title":"Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances","volume":"241","author":"Lau","year":"2017","journal-title":"J. Pathol."},{"issue":"24","key":"10.1016\/j.lfs.2024.122806_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415791","article-title":"Genetic and diet-induced animal models for non-alcoholic fatty liver disease (NAFLD) research","volume":"23","author":"Flessa","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.lfs.2024.122806_bb0240","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/advances\/nmaa081","article-title":"Animal models of fibrosis in nonalcoholic steatohepatitis: do they reflect human disease?","volume":"11","author":"Ipsen","year":"2020","journal-title":"Adv. Nutr."},{"key":"10.1016\/j.lfs.2024.122806_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101143","article-title":"Metabolic drivers of non-alcoholic fatty liver disease","volume":"50","author":"Bence","year":"2021","journal-title":"Mol. Metab."},{"issue":"27","key":"10.1016\/j.lfs.2024.122806_bb0250","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.8641","article-title":"Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0255","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/ijms21010360","article-title":"Antrodan alleviates high-fat and high-fructose diet-induced fatty liver disease in C57BL\/6 mice model via AMPK\/Sirt1\/SREBP-1c\/PPAR\u03b3 pathway","volume":"21","author":"Chyau","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb0260","doi-asserted-by":"crossref","first-page":"G345","DOI":"10.1152\/ajpgi.00055.2020","article-title":"The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"319","author":"Harris","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb0265","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jhep.2016.05.005","article-title":"A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer","volume":"65","author":"Asgharpour","year":"2016","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.lfs.2024.122806_bb0270","doi-asserted-by":"crossref","first-page":"9996","DOI":"10.3390\/ijms24129996","article-title":"Non-alcoholic fatty liver disease: translating disease mechanisms into therapeutics using animal models","volume":"24","author":"Basha","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.lfs.2024.122806_bb0275","first-page":"G762","article-title":"Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice","volume":"302","author":"Trevaskis","year":"2012","journal-title":"Am. J. Phys. Cell Physiol."},{"issue":"12","key":"10.1016\/j.lfs.2024.122806_bb0280","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s42255-022-00700-y","article-title":"A researcher\u2019s guide to preclinical mouse NASH models","volume":"4","author":"Gallage","year":"2022","journal-title":"Nat. Metab."},{"issue":"45","key":"10.1016\/j.lfs.2024.122806_bb0285","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.3748\/wjg.v18.i45.6546","article-title":"Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease","volume":"18","author":"Li","year":"2012","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.lfs.2024.122806_bb0290","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.metabol.2015.08.018","article-title":"Genetics of nonalcoholic fatty liver disease","volume":"65","author":"Dongiovanni","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.lfs.2024.122806_bb0295","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/HMER.S125718","article-title":"PNPLA3 expression and its impact on the liver: current perspectives","volume":"9","author":"Bruschi","year":"2017","journal-title":"Hepat. Med."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0300","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1194\/jlr.P067454","article-title":"Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study1","volume":"58","author":"Krawczyk","year":"2017","journal-title":"J. Lipid Res."},{"issue":"6","key":"10.1016\/j.lfs.2024.122806_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100728","article-title":"African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population","volume":"27","author":"Cavalcante","year":"2022","journal-title":"Ann. Hepatol."},{"issue":"6","key":"10.1016\/j.lfs.2024.122806_bb0310","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20160385","article-title":"Liver glucose metabolism in humans","volume":"36","author":"Adeva-Andany","year":"2016","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.lfs.2024.122806_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101115","article-title":"Hepatic lipid droplets: a balancing act between energy storage and metabolic dysfunction in NAFLD","volume":"50","author":"Mashek","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.lfs.2024.122806_bb0320","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.mce.2018.10.014","article-title":"Role of HSD17B13 in the liver physiology and pathophysiology","volume":"489","author":"Su","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"issue":"7","key":"10.1016\/j.lfs.2024.122806_bb0325","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3390\/jpm11070619","article-title":"Is HSD17B13 genetic variant a protector for liver dysfunction? Future perspective as a potential therapeutic target","volume":"11","author":"Motomura","year":"2021","journal-title":"J. Pers. Med."},{"issue":"12","key":"10.1016\/j.lfs.2024.122806_bb0330","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/apt.15738","article-title":"The emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis","volume":"51","author":"Carlsson","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0335","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s43042-023-00433-x","article-title":"Genetic and metabolic aspects of non-alcoholic fatty liver disease (NAFLD) pathogenicity","volume":"24","author":"Samarasinghe","year":"2023","journal-title":"Egypt. J. Med. Hum. Genet."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0340","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/03602530601093489","article-title":"Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies","volume":"39","author":"Hewitt","year":"2007","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.lfs.2024.122806_bb0345","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0074-7696(06)60002-8","article-title":"Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification","volume":"260","author":"Iyanagi","year":"2007","journal-title":"Int. Rev. Cytol."},{"issue":"7","key":"10.1016\/j.lfs.2024.122806_bb0350","first-page":"601","article-title":"Pharmacokinetic drug-drug interaction and their implication in clinical management","volume":"18","author":"Palleria","year":"2013","journal-title":"J. Res. Med. Sci."},{"key":"10.1016\/j.lfs.2024.122806_bb0355","series-title":"Studies in Natural Products Chemistry","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/B978-0-444-64179-3.00009-8","volume":"Vol. 59","author":"Nanjappan","year":"2018"},{"key":"10.1016\/j.lfs.2024.122806_bb0360","series-title":"Evidence Based Validation of Traditional Medicines: A Comprehensive Approach","first-page":"469","author":"Surendran","year":"2021"},{"issue":"6","key":"10.1016\/j.lfs.2024.122806_bb0365","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cgh.2011.03.020","article-title":"Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008","volume":"9","author":"Younossi","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0370","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3390\/ijms21020604","article-title":"The role of CYP450 drug metabolism in precision cardio-oncology","volume":"21","author":"Fatunde","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0375","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.lfs.2024.122806_bb0380","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/03602530701690366","article-title":"Drug-metabolizing enzymes in the skin of man, rat, and pig","volume":"39","author":"Oesch","year":"2007","journal-title":"Drug Metab. Rev."},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb0385","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.bbagen.2006.09.016","article-title":"Mammalian cytochromes P450\u2014importance of tissue specificity","volume":"1770","author":"Seliskar","year":"2007","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.lfs.2024.122806_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112377","article-title":"CYP450 drug inducibility in NAFLD via an in vitro hepatic model: understanding drug-drug interactions in the fatty liver","volume":"146","author":"Rey-Bedon","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"23","key":"10.1016\/j.lfs.2024.122806_bb0395","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312808","article-title":"Cytochrome P450 enzymes and drug metabolism in humans","volume":"22","author":"Zhao","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.122806_bb0400","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/978-1-62703-758-7_17","article-title":"Sources of interindividual variability","volume":"1113","author":"Thummel","year":"2014","journal-title":"Methods Mol. Biol."},{"issue":"10","key":"10.1016\/j.lfs.2024.122806_bb0405","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.109.027466","article-title":"Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease","volume":"37","author":"Fisher","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb0410","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3109\/03602532.2011.577781","article-title":"Drug metabolism alterations in nonalcoholic fatty liver disease","volume":"43","author":"Merrell","year":"2011","journal-title":"Drug Metab. Rev."},{"issue":"9","key":"10.1016\/j.lfs.2024.122806_bb0415","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/FPC.0b013e3283540217","article-title":"PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6","volume":"22","author":"McDonagh","year":"2012","journal-title":"Pharmacogenet. Genomics"},{"issue":"6","key":"10.1016\/j.lfs.2024.122806_bb0420","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2174\/1389200033489262","article-title":"Transcriptional regulation of cytochrome p450 2B genes by nuclear receptors","volume":"4","author":"Wang","year":"2003","journal-title":"Curr. Drug Metab."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0425","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/hep.510270121","article-title":"Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis","volume":"27","author":"Weltman","year":"1998","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.lfs.2024.122806_bb0430","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1124\/dmd.110.035899","article-title":"Discovery of a novel allelic variant of CYP2C8, CYP2C8*11, in Asian populations and its clinical effect on the rosiglitazone disposition in vivo","volume":"39","author":"Yeo","year":"2011","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0435","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/toxsci\/kfx253","article-title":"Asking the right questions with animal models: methionine- and choline-deficient model in predicting adverse drug reactions in human NASH","volume":"161","author":"Li","year":"2018","journal-title":"Toxicol. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0440","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40268-016-0166-4","article-title":"Rosiglitazone metabolism in human liver microsomes using a substrate depletion method","volume":"17","author":"Bazargan","year":"2017","journal-title":"Drugs R D"},{"issue":"6","key":"10.1016\/j.lfs.2024.122806_bb0445","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s11095-018-2389-2","article-title":"Tissue distribution and gender-specific protein expression of cytochrome P450 in five mouse genotypes with a background of FVB","volume":"35","author":"Chen","year":"2018","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0450","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.21840","article-title":"In vivo cytochrome P450 activity alterations in diabetic nonalcoholic steatohepatitis mice","volume":"31","author":"Li","year":"2017","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"10","key":"10.1016\/j.lfs.2024.122806_bb0455","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.clinre.2011.04.015","article-title":"Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role","volume":"35","author":"Aubert","year":"2011","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"10","key":"10.1016\/j.lfs.2024.122806_bb0460","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1124\/dmd.115.065979","article-title":"CYP3A activity and expression in nonalcoholic fatty liver disease","volume":"43","author":"Woolsey","year":"2015","journal-title":"Drug Metab. Dispos."},{"issue":"9","key":"10.1016\/j.lfs.2024.122806_bb0465","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3390\/ph13090222","article-title":"Nonalcoholic fatty liver disease (NAFLD) and hepatic cytochrome P450 (CYP) enzymes","volume":"13","author":"Jamwal","year":"2020","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0470","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/FPC.0b013e32834c6efd","article-title":"PharmGKB summary: very important pharmacogene information for CYP1A2","volume":"22","author":"Thorn","year":"2012","journal-title":"Pharmacogenet. Genomics"},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb0475","first-page":"391","article-title":"The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects","volume":"76","author":"Lynch","year":"2007","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.lfs.2024.122806_bb0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-7075-5-27","article-title":"Role of cytochrome P450 in drug interactions","volume":"5","author":"Bibi","year":"2008","journal-title":"Nutr. Metab."},{"issue":"5","key":"10.1016\/j.lfs.2024.122806_bb0485","article-title":"Transcriptomic analysis across liver diseases reveals disease-modulating activation of constitutive androstane receptor in cholestasis","volume":"2","author":"Mathur","year":"2020","journal-title":"JHEP Rep."},{"key":"10.1016\/j.lfs.2024.122806_bb0490","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.fct.2018.01.029","article-title":"Cytochrome P450 1A1 (CYP1A1) protects against nonalcoholic fatty liver disease caused by Western diet containing benzo[a]pyrene in mice","volume":"113","author":"Uno","year":"2018","journal-title":"Food Chem. Toxicol."},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0495","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s13770-020-00297-x","article-title":"Functional analysis of induced human ballooned hepatocytes in a cell sheet-based three dimensional model","volume":"18","author":"Gao","year":"2021","journal-title":"J. Tissue Eng. Regen. Med."},{"issue":"6","key":"10.1016\/j.lfs.2024.122806_bb0500","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2125.1998.00721.x","article-title":"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism","volume":"45","author":"Miners","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0505","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bcp.12802","article-title":"Can paracetamol (acetaminophen) be administered to patients with liver impairment?","volume":"81","author":"Hayward","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2024.122806_bb0510","series-title":"Doctor of Philosophy","author":"Cobbina","year":"2018"},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0515","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1124\/dmd.110.035691","article-title":"Ethanol induction of CYP2A5: permissive role for CYP2E1","volume":"39","author":"Lu","year":"2011","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.lfs.2024.122806_bb0520","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.apsb.2016.07.016","article-title":"Insights into CYP2B6-mediated drug\u2013drug interactions","volume":"6","author":"Hedrich","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.lfs.2024.122806_bb0525","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.692234","article-title":"CYP2B6 functional variability in drug metabolism and exposure across populations\u2014implication for drug safety, dosing, and individualized therapy","volume":"12","author":"Langmia","year":"2021","journal-title":"Front. Genet."},{"issue":"4","key":"10.1016\/j.lfs.2024.122806_bb0530","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.bpg.2014.07.008","article-title":"Non-alcoholic fatty liver disease, obesity and the metabolic syndrome","volume":"28","author":"Dietrich","year":"2014","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"issue":"27","key":"10.1016\/j.lfs.2024.122806_bb0535","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1021\/acs.jafc.6b01663","article-title":"Effects of nonalcoholic fatty liver disease on hepatic CYP2B1 and in vivo bupropion disposition in rats fed a high-fat or methionine\/choline-deficient diet","volume":"64","author":"Cho","year":"2016","journal-title":"J. Agric. Food Chem."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0540","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.dmpk.2017.11.116","article-title":"Hepatic lipid accumulation in experimental HepaRG model for steatosis influences bupropion biotransformation","volume":"33","author":"Saravanakumar","year":"2018","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0545","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/03602532.2020.1758714","article-title":"Inhibition of CYP2C9 by natural products: insight into the potential risk of herb-drug interactions","volume":"52","author":"Wang","year":"2020","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.lfs.2024.122806_bb0550","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.taap.2018.05.021","article-title":"Investigation of nonalcoholic fatty liver disease-induced drug metabolism by comparative global toxicoproteomics","volume":"352","author":"Na","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0555","doi-asserted-by":"crossref","first-page":"481","DOI":"10.18433\/jpps30022","article-title":"Non-alcoholic steatohepatitis (NASH) drug discovery - building a consensus on ADME screening tools and clinical pharmacology strategies to aid candidate development","volume":"21","author":"Dash","year":"2018","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.lfs.2024.122806_bb0560","doi-asserted-by":"crossref","first-page":"11963","DOI":"10.3390\/ijms140611963","article-title":"In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD)","volume":"14","author":"Kanuri","year":"2013","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb0565","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1365-2125.1999.00030.x","article-title":"Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone","volume":"48","author":"Baldwin","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.lfs.2024.122806_bb0570","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1080\/14740338.2017.1389891","article-title":"Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?","volume":"16","author":"Seripa","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0575","doi-asserted-by":"crossref","first-page":"17","DOI":"10.29245\/2578-2959\/2018\/2.1120","article-title":"Pharmacogenetics and psychiatric care: a review and commentary","volume":"2","author":"Butler","year":"2018","journal-title":"J. Ment. Health Clin. Psychol."},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0580","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3748\/wjg.v23.i2.204","article-title":"Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease","volume":"23","author":"Kostrzewski","year":"2017","journal-title":"World J. Gastroenterol."},{"issue":"12","key":"10.1016\/j.lfs.2024.122806_bb0585","first-page":"814","article-title":"Drug-drug interactions of \u03b2-adrenoceptor blockers","volume":"53","author":"Brodde","year":"2003","journal-title":"Arzneimittelforschung"},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb0590","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1515\/DMDI.2003.19.3.189","article-title":"A molecular model of CYP2D6 constructed by homology with the CYP2C5 crystallographic template: investigation of enzyme-substrate interactions","volume":"19","author":"Lewis","year":"2003","journal-title":"Drug Metabol. Drug Interact."},{"issue":"4","key":"10.1016\/j.lfs.2024.122806_bb0595","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1124\/dmd.110.036806","article-title":"Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis","volume":"39","author":"Li","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.lfs.2024.122806_bb0600","doi-asserted-by":"crossref","first-page":"98","DOI":"10.18433\/jpps30268","article-title":"Effects of orotic acid-induced non-alcoholic fatty liver on the pharmacokinetics of metoprolol and its metabolites in rats","volume":"22","author":"Bang","year":"2019","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb0605","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1517\/17425250903540238","article-title":"CYP2E1 and risk of chemically mediated cancers","volume":"6","author":"Trafalis","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0610","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2478\/10004-1254-60-2009-1885","article-title":"Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk","volume":"60","author":"Bozina","year":"2009","journal-title":"Arh. Hig. Rada Toksikol."},{"key":"10.1016\/j.lfs.2024.122806_bb0615","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-3-030-22254-3_6","article-title":"Contributing roles of CYP2E1 and other cytochrome P450 isoforms in alcohol-related tissue injury and carcinogenesis","volume":"1164","author":"Song","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.lfs.2024.122806_bb0620","series-title":"An Investigation of the Induction of Hepatic CYP2E1 by Low Doses of Nicotine in the Rat","author":"Micu","year":"2003"},{"issue":"12","key":"10.1016\/j.lfs.2024.122806_bb0625","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.7314\/APJCP.2012.13.12.6505","article-title":"CYP2E1*5B, CYP2E1*6, CYP2E1*7B, CYP2E1*2, and CYP2E1*3 allele frequencies in Iranian populations","volume":"13","author":"Shahriary","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"15","key":"10.1016\/j.lfs.2024.122806_bb0630","doi-asserted-by":"crossref","first-page":"8221","DOI":"10.3390\/ijms22158221","article-title":"CYP2E1 in alcoholic and non-alcoholic liver injury. Roles of ROS, reactive intermediates and lipid overload","volume":"22","author":"Harjum\u00e4ki","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"20","key":"10.1016\/j.lfs.2024.122806_bb0635","doi-asserted-by":"crossref","first-page":"12063","DOI":"10.1074\/jbc.271.20.12063","article-title":"Role of CYP2E1 in the hepatotoxicity of acetaminophen","volume":"271","author":"Lee","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb0640","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/1874467208666150817111114","article-title":"Role of CYP2E1 in mitochondrial dysfunction and hepatic injury by alcohol and non-alcoholic substances","volume":"10","author":"Abdelmegeed","year":"2017","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.lfs.2024.122806_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115160","article-title":"Cytochrome P450 2E1 gene knockout or inhibition prevents obesity induced by high-fat diet via regulating energy expenditure","volume":"202","author":"Zhang","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0650","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.39.1.1","article-title":"Cytochrome P-450 3A4: regulation and role in drug metabolism","volume":"39","author":"Guengerich","year":"1999","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0655","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab. Rev."},{"issue":"9","key":"10.1016\/j.lfs.2024.122806_bb0660","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2174\/138920012803341302","article-title":"Drug disposition in pathophysiological conditions","volume":"13","author":"Gandhi","year":"2012","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.lfs.2024.122806_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173655","article-title":"The pharmacological activity of berberine, a review for liver protection","volume":"890","author":"Zhou","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.lfs.2024.122806_bb0670","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1021\/acs.molpharmaceut.8b00159","article-title":"Nonalcoholic fatty liver disease and diabetes are associated with decreased CYP3A4 protein expression and activity in human liver","volume":"15","author":"Jamwal","year":"2018","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.lfs.2024.122806_bb0675","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0050097","article-title":"Structural and chemical profiling of the human cytosolic sulfotransferases","volume":"5","author":"Allali-Hassani","year":"2007","journal-title":"PLoS Biol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0680","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/toxsci\/kfj061","article-title":"Human sulfotransferases and their role in chemical metabolism","volume":"90","author":"Gamage","year":"2006","journal-title":"Toxicol. Sci."},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb0685","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1124\/dmd.112.048439","article-title":"Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease","volume":"41","author":"Hardwick","year":"2013","journal-title":"Drug Metab. Dispos."},{"issue":"9","key":"10.1016\/j.lfs.2024.122806_bb0690","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1124\/dmd.113.050930","article-title":"Downregulation of sulfotransferase expression and activity in diseased human livers","volume":"41","author":"Yalcin","year":"2013","journal-title":"Drug Metab. Dispos."},{"issue":"8","key":"10.1016\/j.lfs.2024.122806_bb0695","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1124\/dmd.109.027565","article-title":"Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity","volume":"37","author":"Cheng","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.lfs.2024.122806_bb0700","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/nu11040872","article-title":"Oxidative stress and non-alcoholic fatty liver disease: effects of omega-3 fatty acid supplementation","volume":"11","author":"Yang","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.lfs.2024.122806_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2019.114664","article-title":"Altered bile acid composition and disposition in a mouse model of non-alcoholic steatohepatitis","volume":"379","author":"Suga","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb0710","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/hep.20838","article-title":"A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease","volume":"42","author":"Younossi","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.lfs.2024.122806_bb0715","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s11695-010-0078-2","article-title":"Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease","volume":"20","author":"Stepanova","year":"2010","journal-title":"Obes. Surg."},{"issue":"9","key":"10.1016\/j.lfs.2024.122806_bb0720","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1124\/dmd.113.050930","article-title":"Downregulation of sulfotransferase expression and activity in diseased human livers","volume":"41","author":"Yalcin","year":"2013","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0725","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5507\/bp.2010.017","article-title":"Phase II drug metabolizing enzymes","volume":"154","author":"Jancova","year":"2010","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub."},{"issue":"27","key":"10.1016\/j.lfs.2024.122806_bb0730","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.2174\/0929867325666180226111311","article-title":"UDP-glucuronosyltransferases: structure, function and drug design studies","volume":"25","author":"Mano","year":"2018","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb0735","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/pharmaceutics9030032","article-title":"Revisiting the latency of uridine diphosphate-glucuronosyltransferases (UGTs)\u2014how does the endoplasmic reticulum membrane influence their function?","volume":"9","author":"Liu","year":"2017","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0740","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1152\/physrev.00058.2017","article-title":"The UDP-glycosyltransferase (UGT) superfamily: new members, new functions, and novel paradigms","volume":"99","author":"Meech","year":"2019","journal-title":"Physiol. Rev."},{"issue":"1\u20133","key":"10.1016\/j.lfs.2024.122806_bb0745","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejphar.2013.09.024","article-title":"Dysregulations of UDP-glucuronosyltransferases in rats with valproic acid and high fat diet induced fatty liver","volume":"721","author":"Zhang","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0750","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/dmd.107.017731","article-title":"Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferator-activated receptor \u03b1 in male rats fed a high-fat and high-sucrose diet","volume":"36","author":"Osabe","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0755","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12986-020-00456-w","article-title":"High fat diet significantly changed the global gene expression profile involved in hepatic drug metabolism and pharmacokinetic system in mice","volume":"17","author":"He","year":"2020","journal-title":"Nutr. Metab."},{"key":"10.1016\/j.lfs.2024.122806_bb0760","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.phrs.2017.05.001","article-title":"UDP-glucuronosyltransferases (UGTs) and their related metabolic cross-talk with internal homeostasis: a systematic review of UGT isoforms for precision medicine","volume":"121","author":"Yang","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.lfs.2024.122806_bb0765","series-title":"Hong Kong University of Science and Technology (Hong Kong)","author":"Li","year":"2020"},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb0770","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1124\/dmd.112.048439","article-title":"Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease","volume":"41","author":"Hardwick","year":"2013","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0775","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1124\/dmd.106.012070","article-title":"Tissue-and gender-specific mRNA expression of UDP-glucuronosyltransferases (UGTs) in mice","volume":"35","author":"Buckley","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.lfs.2024.122806_bb0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.etap.2022.103967","article-title":"Valproic acid induced liver injury: an insight into molecular toxicological mechanism","volume":"95","author":"Ezhilarasan","year":"2022","journal-title":"Environ. Toxicol. Pharmacol."},{"issue":"1\u20133","key":"10.1016\/j.lfs.2024.122806_bb0785","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejphar.2013.09.024","article-title":"Dysregulations of UDP-glucuronosyltransferases in rats with valproic acid and high fat diet induced fatty liver","volume":"721","author":"Zhang","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.lfs.2024.122806_bb0790","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1016\/j.bbagen.2012.09.018","article-title":"Glutathione catalysis and the reaction mechanisms of glutathione-dependent enzymes","volume":"1830","author":"Deponte","year":"2013","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"issue":"6","key":"10.1016\/j.lfs.2024.122806_bb0795","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1007\/s11356-012-0909-x","article-title":"Glutathione, glutathione S-transferase, and glutathione conjugates, complementary markers of oxidative stress in aquatic biota","volume":"19","author":"Hellou","year":"2012","journal-title":"Environ. Sci. Pollut. Res. Int."},{"issue":"4","key":"10.1016\/j.lfs.2024.122806_bb0800","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/10715769900300851","article-title":"Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress","volume":"31","author":"Hayes","year":"1999","journal-title":"Free Radic. Res."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0805","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/mnfr.201300522","article-title":"Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds","volume":"58","author":"Pan","year":"2014","journal-title":"Mol. Nutr. Food Res."},{"issue":"7","key":"10.1016\/j.lfs.2024.122806_bb0810","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.3390\/ijms23074015","article-title":"Anti-obesity and anti-hyperglycemic effects of Meretrix lusoria protamex hydrolysate in ob\/ob mice","volume":"23","author":"Kim","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.lfs.2024.122806_bb0815","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1124\/dmd.110.035006","article-title":"Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease","volume":"38","author":"Hardwick","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"11","key":"10.1016\/j.lfs.2024.122806_bb0820","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1158\/1055-9965.EPI-09-0589","article-title":"CYP1A2, GSTM1, and GSTT1 polymorphisms and diet effects on CYP1A2 activity in a crossover feeding trial","volume":"18","author":"Peterson","year":"2009","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0825","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1096\/fj.04-3640fje","article-title":"Differential gene expression profiling of short and long term denervated muscle","volume":"20","author":"Batt","year":"2006","journal-title":"FASEB J."},{"issue":"39","key":"10.1016\/j.lfs.2024.122806_bb0830","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.2174\/0929867323666161024154457","article-title":"Expression and regulation of drug transporters and metabolizing enzymes in the human gastrointestinal tract","volume":"23","author":"Drozdzik","year":"2016","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb0835","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/00129785-200303030-00002","article-title":"Cancer drugs, genetic variation and the glutathione-S-transferase gene family","volume":"3","author":"Townsend","year":"2003","journal-title":"Am. J. Pharmacogenomics"},{"issue":"6","key":"10.1016\/j.lfs.2024.122806_bb0840","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jceh.2019.05.005","article-title":"Childhood and adolescent nonalcoholic fatty liver disease: is it different from adults?","volume":"9","author":"Fitzpatrick","year":"2019","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"12","key":"10.1016\/j.lfs.2024.122806_bb0845","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1124\/dmd.117.077644","article-title":"Pediatric cytochrome P450 activity alterations in nonalcoholic steatohepatitis","volume":"45","author":"Li","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.lfs.2024.122806_bb0850","article-title":"Regulation of the cytochrome P450 epoxyeicosanoid pathway is associated with distinct histologic features in pediatric non-alcoholic fatty liver disease","volume":"164","author":"Kalveram","year":"2021","journal-title":"PLEFA"},{"issue":"11","key":"10.1016\/j.lfs.2024.122806_bb0855","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1021\/acsmedchemlett.0c00202","article-title":"Biotransformation: impact and application of metabolism in drug discovery","volume":"11","author":"Shanu-Wilson","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.lfs.2024.122806_bb0860","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/17425255.2017.1314461","article-title":"Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease","volume":"13","author":"Dietrich","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0865","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jhep.2012.08.018","article-title":"CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease","volume":"58","author":"Leung","year":"2013","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb0870","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.freeradbiomed.2011.10.481","article-title":"Physiological effects of oxidized phospholipids and their cellular signaling mechanisms in inflammation","volume":"52","author":"Greig","year":"2012","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0875","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.freeradbiomed.2011.09.031","article-title":"Inflammation-related gene expression by lipid oxidation-derived products in the progression of atherosclerosis","volume":"52","author":"Leonarduzzi","year":"2012","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0880","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00204-020-02916-x","article-title":"Transcriptional and post-transcriptional regulation of the pregnane X receptor: a rationale for interindividual variability in drug metabolism","volume":"95","author":"Smutny","year":"2021","journal-title":"Arch. Toxicol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0885","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hepres.2003.08.001","article-title":"CYP2E1: from ASH to NASH","volume":"28","author":"Lieber","year":"2004","journal-title":"Hepatol. Res."},{"issue":"4","key":"10.1016\/j.lfs.2024.122806_bb0890","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jhep.2012.05.019","article-title":"Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis","volume":"57","author":"Abdelmegeed","year":"2012","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.lfs.2024.122806_bb0895","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10565-011-9188-4","article-title":"Cytochrome P450 2E1 and hyperglycemia-induced liver injury","volume":"27","author":"Dey","year":"2011","journal-title":"Cell Biol. Toxicol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0900","article-title":"Effect of BI-1 on insulin resistance through regulation of CYP2E1","volume":"6","author":"Lee","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2024.122806_bb0905","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/172493","article-title":"P2X7 receptor as a key player in oxidative stress-driven cell fate in nonalcoholic steatohepatitis","volume":"2015","author":"Chatterjee","year":"2015","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"7","key":"10.1016\/j.lfs.2024.122806_bb0910","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1089\/ars.2013.5486","article-title":"Reactive oxygen and nitrogen species in steatotic hepatocytes: a molecular perspective on the pathophysiology of ischemia-reperfusion injury in the fatty liver","volume":"21","author":"Reiniers","year":"2014","journal-title":"Antioxid. Redox Signal."},{"issue":"7","key":"10.1016\/j.lfs.2024.122806_bb0915","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.ajpath.2015.03.024","article-title":"NADPH oxidase\u2013derived peroxynitrite drives inflammation in mice and human nonalcoholic steatohepatitis via TLR4-lipid raft recruitment","volume":"185","author":"Das","year":"2015","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.lfs.2024.122806_bb0920","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.redox.2014.09.004","article-title":"Regulation of the effects of CYP2E1-induced oxidative stress by JNK signaling","volume":"3","author":"Schattenberg","year":"2014","journal-title":"Redox Biol."},{"issue":"1\u20132","key":"10.1016\/j.lfs.2024.122806_bb0925","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mrfmmm.2004.04.021","article-title":"Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1","volume":"569","author":"Gonzalez","year":"2005","journal-title":"Mutat. Res."},{"issue":"5","key":"10.1016\/j.lfs.2024.122806_bb0930","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3390\/cancers14051116","article-title":"The role of purinergic P2X7 receptor in inflammation and cancer: novel molecular insights and clinical applications","volume":"14","author":"Rotondo","year":"2022","journal-title":"Cancers"},{"issue":"22","key":"10.1016\/j.lfs.2024.122806_bb0935","doi-asserted-by":"crossref","first-page":"8454","DOI":"10.3390\/ijms21228454","article-title":"Structural and functional basis for understanding the biological significance of P2X7 receptor","volume":"21","author":"Mart\u00ednez-Cuesta","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.122806_bb0940","series-title":"CXCL10, an IFN-\u03b3-Induced Chemokine, Is Required for the Development of Depigmentation in a Mouse Model of Vitiligo","author":"Rashighi","year":"2012"},{"key":"10.1016\/j.lfs.2024.122806_bb0945","series-title":"Modulation de la r\u00e9ponse immunitaire par des agonistes de la voie de signalisation TLR\/IL-1R dans le mod\u00e8le d asthme","author":"\u00c9mond","year":"2010"},{"issue":"17","key":"10.1016\/j.lfs.2024.122806_bb0950","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713065","article-title":"Research progress of pyroptosis in fatty liver disease","volume":"24","author":"Li","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.lfs.2024.122806_bb0955","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.bbrc.2015.02.011","article-title":"Extracellular ATP induces P2X7 receptor activation in mouse Kupffer cells, leading to release of IL-1\u03b2, HMGB1, and PGE2, decreased MHC class I expression and necrotic cell death","volume":"458","author":"Toki","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.lfs.2024.122806_bb0960","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3390\/cells9041047","article-title":"The P2X7 receptor and NLRP3 axis in non-alcoholic fatty liver disease: a brief review","volume":"9","author":"Rossato","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.lfs.2024.122806_bb0965","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-nutr-071812-161148","article-title":"AMP-activated protein kinase: maintaining energy homeostasis at the cellular and whole-body levels","volume":"34","author":"Hardie","year":"2014","journal-title":"Annu. Rev. Nutr."},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb0970","first-page":"175","article-title":"The endocrine control of metabolism","volume":"29","author":"Engel","year":"1953","journal-title":"Bull. N. Y. Acad. Med."},{"key":"10.1016\/j.lfs.2024.122806_bb0975","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jhevol.2014.06.013","article-title":"Metabolism as a tool for understanding human brain evolution: lipid energy metabolism as an example","volume":"77","author":"Wang","year":"2014","journal-title":"J. Hum. Evol."},{"key":"10.1016\/j.lfs.2024.122806_bb0980","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s13105-011-0112-4","article-title":"The biochemistry of ketogenesis and its role in weight management, neurological disease and oxidative stress","volume":"68","author":"McPherson","year":"2012","journal-title":"J. Physiol. Biochem."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb0985","first-page":"1","article-title":"GW501516 (Cardarine): pharmacological and clinical effects","volume":"5","author":"Bianchi","year":"2023","journal-title":"Genet. Mol. Med."},{"issue":"8","key":"10.1016\/j.lfs.2024.122806_bb0990","doi-asserted-by":"crossref","first-page":"8711","DOI":"10.1096\/fj.201802842RR","article-title":"Role of branched-chain amino acid\u2013catabolizing enzymes in intertissue signaling, metabolic remodeling, and energy homeostasis","volume":"33","author":"Biswas","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.lfs.2024.122806_bb0995","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/501739","article-title":"Regulation of bile acid and cholesterol metabolism by PPARs","volume":"2009","author":"Li","year":"2009","journal-title":"PPAR Res."},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb1000","doi-asserted-by":"crossref","first-page":"G554","DOI":"10.1152\/ajpgi.00223.2019","article-title":"Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy","volume":"318","author":"Chiang","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"5","key":"10.1016\/j.lfs.2024.122806_bb1005","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/joim.12803","article-title":"Inflammation of brown\/beige adipose tissues in obesity and metabolic disease","volume":"284","author":"Villarroya","year":"2018","journal-title":"J. Intern. Med."},{"issue":"8","key":"10.1016\/j.lfs.2024.122806_bb1010","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3390\/cells11081251","article-title":"Effects of oxysterols on immune cells and related diseases","volume":"11","author":"de Freitas","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.lfs.2024.122806_bb1015","series-title":"Proceedings of the First Neurological Disorders Summit (NDS-2015)","article-title":"Neurology & experimental neuroscience","author":"Blum","year":"2019"},{"key":"10.1016\/j.lfs.2024.122806_bb1020","author":"Evangelakos"},{"issue":"11","key":"10.1016\/j.lfs.2024.122806_bb1025","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","article-title":"Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome","volume":"2","author":"Yki-J\u00e4rvinen","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.lfs.2024.122806_bb1030","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-physiol-012110-142233","article-title":"Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport","volume":"73","author":"Jia","year":"2011","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.lfs.2024.122806_bb1035","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2548154","article-title":"Hypoxic signaling and cholesterol lipotoxicity in fatty liver disease progression","volume":"2018","author":"Tirosh","year":"2018","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"4","key":"10.1016\/j.lfs.2024.122806_bb1040","doi-asserted-by":"crossref","first-page":"6184","DOI":"10.3390\/ijms15046184","article-title":"Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease","volume":"15","author":"Jung","year":"2014","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb1045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2174\/157016111793744715","article-title":"Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe in NAFLD\/NASH treatment","volume":"9","author":"Yoshida","year":"2011","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"10","key":"10.1016\/j.lfs.2024.122806_bb1050","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.15252\/emmm.201404000","article-title":"Evolving targets for lipid-modifying therapy","volume":"6","author":"Do","year":"2014","journal-title":"EMBO Mol. Med."},{"issue":"12","key":"10.1016\/j.lfs.2024.122806_bb1055","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1021\/jf200757h","article-title":"Microalga decreases plasma cholesterol by down-regulation of intestinal NPC1L1, hepatic LDL receptor, and HMG-CoA reductase","volume":"59","author":"Chen","year":"2011","journal-title":"J. Agric. Food Chem."},{"issue":"10","key":"10.1016\/j.lfs.2024.122806_bb1060","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1194\/jlr.M600174-JLR200","article-title":"Localization and role of NPC1L1 in cholesterol absorption in human intestine","volume":"47","author":"San\u00e9","year":"2006","journal-title":"J. Lipid Res."},{"issue":"13","key":"10.1016\/j.lfs.2024.122806_bb1065","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1016\/j.febslet.2010.03.030","article-title":"NPC1L1 and cholesterol transport","volume":"584","author":"Betters","year":"2010","journal-title":"FEBS Lett."},{"issue":"4","key":"10.1016\/j.lfs.2024.122806_bb1070","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1242\/jcs.107.4.1065","article-title":"Molecular cloning and characterization of a novel liver-specific transport protein","volume":"107","author":"Simonson","year":"1994","journal-title":"J. Cell Sci."},{"issue":"4","key":"10.1016\/j.lfs.2024.122806_bb1075","first-page":"293","volume":"8","author":"Meier","year":"1988","journal-title":"Transport polarity of hepatocytes"},{"issue":"9","key":"10.1016\/j.lfs.2024.122806_bb1080","first-page":"2784","article-title":"A guide to plasma membrane solute carrier proteins","volume":"288","author":"Pizzagalli","year":"2021","journal-title":"FASEB J."},{"issue":"6","key":"10.1016\/j.lfs.2024.122806_bb1085","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1039\/C6MD00005C","article-title":"SLC transporters: structure, function, and drug discovery","volume":"7","author":"Colas","year":"2016","journal-title":"MedChemComm"},{"key":"10.1016\/j.lfs.2024.122806_bb1090","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3389\/fphar.2014.00274","article-title":"Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans","volume":"5","author":"Lu","year":"2014","journal-title":"Front. Pharmacol."},{"issue":"3\u20134","key":"10.1016\/j.lfs.2024.122806_bb1095","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1081\/DMR-200033473","article-title":"The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance","volume":"36","author":"Hoffmann","year":"2004","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.lfs.2024.122806_bb1100","series-title":"Drug Transporters in Drug Disposition, Effects and Toxicity","first-page":"13","author":"Liu","year":"2019"},{"key":"10.1016\/j.lfs.2024.122806_bb1105","series-title":"Functional Impact of Genetic Variants, Medications, and Disease on Hepatic Bile Acid Transporters","author":"Yang","year":"2014"},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb1110","first-page":"1","article-title":"Current models for predicting drug-induced cholestasis: the role of hepatobiliary transport system","volume":"20","author":"Jazaeri","year":"2021","journal-title":"Iran. J. Pharm. Res."},{"key":"10.1016\/j.lfs.2024.122806_bb1115","series-title":"Transporters in Drug Development. AAPS Advances in the Pharmaceutical Sciences Series","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4614-8229-1_9","article-title":"Analysis of hepatic transport proteins","volume":"Vol. 7","author":"Yang","year":"2013"},{"issue":"4","key":"10.1016\/j.lfs.2024.122806_bb1120","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1586\/17512433.2014.910111","article-title":"Understanding and preventing drug\u2013drug and drug\u2013gene interactions","volume":"7","author":"Tannenbaum","year":"2014","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.lfs.2024.122806_bb1125","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/cpt.1098","article-title":"Influence of transporter polymorphisms on drug disposition and response: a perspective from the international transporter consortium","volume":"104","author":"Yee","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.lfs.2024.122806_bb1130","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s40262-018-0650-9","article-title":"Complex drug\u2013drug\u2013gene\u2013disease interactions involving cytochromes P450: systematic review of published case reports and clinical perspectives","volume":"57","author":"Storelli","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.lfs.2024.122806_bb1135","author":"Ferslew","year":"2014","journal-title":"University of North Carolina at Chapel Hill Graduate School"},{"key":"10.1016\/j.lfs.2024.122806_bb1140","author":"Ali","year":"2019","journal-title":"University of North Carolina at Chapel Hill Graduate School"},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb1145","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/clpt.2013.74","article-title":"Emerging transporters of clinical importance: an update from the International Transporter Consortium","volume":"94","author":"Hillgren","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.lfs.2024.122806_bb1150","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41575-021-00566-7","article-title":"Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology","volume":"19","author":"Fuchs","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.lfs.2024.122806_bb1155","series-title":"Organic Anion Transporting Polypeptides (Oatps\/OATPs)","author":"Yarim","year":"2009"},{"issue":"16","key":"10.1016\/j.lfs.2024.122806_bb1160","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jnci\/92.16.1295","article-title":"A family of drug transporters: the multidrug resistance-associated proteins","volume":"92","author":"Borst","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"issue":"9","key":"10.1016\/j.lfs.2024.122806_bb1165","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.xphs.2017.04.053","article-title":"Effect of liver disease on hepatic transporter expression and function","volume":"106","author":"Thakkar","year":"2017","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb1170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13318-022-00802-8","article-title":"Hepatic transporters alternations associated with non-alcoholic fatty liver disease (NAFLD): a systematic review","volume":"48","author":"Omidkhoda","year":"2023","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb1175","doi-asserted-by":"crossref","first-page":"G294","DOI":"10.1152\/ajpgi.00541.2007","article-title":"Hepatic Mrp4 induction following acetaminophen exposure is dependent on Kupffer cell function","volume":"295","author":"Campion","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb1180","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/gutjnl-2021-324305","article-title":"Novel therapeutic targets for cholestatic and fatty liver disease","volume":"71","author":"Trauner","year":"2022","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.lfs.2024.122806_bb1185","doi-asserted-by":"crossref","first-page":"G597","DOI":"10.1152\/ajpgi.00310.2017","article-title":"Organic solute transporter OST\u03b1\/\u03b2 is over-expressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury 2","volume":"314","author":"Malinen","year":"2018","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb1190","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1124\/jpet.120.000291","article-title":"Transporter activity changes in nonalcoholic steatohepatitis: assessment with plasma coproporphyrin I and III","volume":"376","author":"Chatterjee","year":"2021","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb1195","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/cpt.2614","article-title":"Considerations for physiologically based modeling in liver disease: from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH)","volume":"113","author":"Murphy","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2024.122806_bb1200","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/liv.13301","article-title":"Pathology of non-alcoholic fatty liver disease","volume":"37","author":"Bedossa","year":"2017","journal-title":"Liver Int."},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb1205","doi-asserted-by":"crossref","first-page":"194","DOI":"10.32074\/1591-951X-242","article-title":"Pathology of non-alcoholic fatty liver disease","volume":"113","author":"Cataldo","year":"2021","journal-title":"Pathologica"},{"key":"10.1016\/j.lfs.2024.122806_bb1210","author":"Pharmaceuticals"},{"issue":"12","key":"10.1016\/j.lfs.2024.122806_bb1215","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1080\/13543784.2020.1839888","article-title":"The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success","volume":"29","author":"Drenth","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb1220","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/13543784.2020.1668375","article-title":"Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH)","volume":"29","author":"Westerouen Van Meeteren","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"17\u201318","key":"10.1016\/j.lfs.2024.122806_bb1225","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.drudis.2012.05.012","article-title":"Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis","volume":"17","author":"Adorini","year":"2012","journal-title":"Drug Discov. Today"},{"issue":"8","key":"10.1016\/j.lfs.2024.122806_bb1230","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.metabol.2016.04.004","article-title":"Pharmacological management of nonalcoholic fatty liver disease","volume":"65","author":"Barb","year":"2016","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb1235","article-title":"Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis","volume":"3","author":"Bhattacharya","year":"2021","journal-title":"JHEP Rep."},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb1240","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2021","journal-title":"Metabolites"},{"issue":"11","key":"10.1016\/j.lfs.2024.122806_bb1245","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1111\/j.1572-0241.2003.08699.x","article-title":"Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis","volume":"98","author":"Harrison","year":"2003","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb1250","first-page":"90","article-title":"Efficacy of orlistat in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"9","author":"Wang","year":"2018","journal-title":"Biomed. Rep."},{"key":"10.1016\/j.lfs.2024.122806_bb1255","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107940","article-title":"Evidence-based pharmacological treatment options for ADHD in children and adolescents","volume":"230","author":"Mechler","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb1260","first-page":"189","article-title":"The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis","volume":"12","author":"Sabuncu","year":"2003","journal-title":"Rom. J. Gastroenterol."},{"issue":"41","key":"10.1016\/j.lfs.2024.122806_bb1265","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.3748\/wjg.v18.i41.5839","article-title":"Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease","volume":"18","author":"Di Minno","year":"2012","journal-title":"World J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.lfs.2024.122806_bb1270","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lfs.2024.122806_bb1275","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jff.2014.04.010","article-title":"Effects of green tea catechins on nonalcoholic steatohepatitis (NASH) patients","volume":"9","author":"Fukuzawa","year":"2014","journal-title":"J. Funct. Foods"},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb1280","doi-asserted-by":"crossref","DOI":"10.1016\/j.phyplu.2021.100021","article-title":"Inhibition of NOX4 by Cissus quadrangularis extract protects from type 2 diabetes induced-steatohepatitis","volume":"1","author":"Syed","year":"2021","journal-title":"Phytomed. Plus"},{"issue":"14","key":"10.1016\/j.lfs.2024.122806_bb1285","article-title":"Curcumin supplementation mitigates NASH development and progression in female Wistar rats","volume":"6","author":"Cunningham","year":"2018","journal-title":"Phys. Rep."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb1290","first-page":"9","article-title":"Silymarin in treatment of non-alcoholic steatohepatitis: a randomized clinical trial","volume":"5","author":"Solhi","year":"2014","journal-title":"Caspian J. Intern. Med."},{"key":"10.1016\/j.lfs.2024.122806_bb1295","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106925","article-title":"Natural products in non-alcoholic fatty liver disease (NAFLD): novel lead discovery for drug development","author":"Wang","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.lfs.2024.122806_bb1300","unstructured":"M. Mesbah Shams, Shiraz The Effects of Zataria Multiflora Boiss (Shirazi's Thyme) on Nonalcoholic Fatty Liver Disease (ThymeLiv), https:\/\/clinicaltrials.gov\/study\/NCT02983669."},{"key":"10.1016\/j.lfs.2024.122806_bb1305","unstructured":"M. Mesbah Shams, Shiraz, Effects of Ginger on Nonalcoholic Fatty Liver Disease in T2DM (GinLivDM), https:\/\/clinicaltrials.gov\/study\/NCT02289235."},{"key":"10.1016\/j.lfs.2024.122806_bb1310","unstructured":"H. Xingxiang, Therapeutic Effects of Compound Zhenzhu Tiaozhi Capsules in NAFLD, https:\/\/clinicaltrials.gov\/study\/NCT03375580."},{"key":"10.1016\/j.lfs.2024.122806_bb1315","unstructured":"T. C. Hospital, Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors, https:\/\/clinicaltrials.gov\/study\/NCT06244550."},{"key":"10.1016\/j.lfs.2024.122806_bb1320","unstructured":"U. o. Malaya, Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD), https:\/\/clinicaltrials.gov\/study\/NCT02006498."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb1325","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.apsb.2019.11.017","article-title":"Herbal drug discovery for the treatment of nonalcoholic fatty liver disease","volume":"10","author":"Yan","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb1330","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1124\/jpet.119.260489","article-title":"A pharmacokinetic natural product-disease-drug interaction: a double hit of silymarin and nonalcoholic steatohepatitis on hepatic transporters in a rat model","volume":"371","author":"Montonye","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb1335","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4103\/ijd.IJD_442_17","article-title":"The curious cases of burn by fig tree leaves","volume":"64","author":"Imen","year":"2019","journal-title":"Indian J. Dermatol."},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb1340","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3109\/03602532.2011.577781","article-title":"Drug metabolism alterations in nonalcoholic fatty liver disease","volume":"43","author":"Merrell","year":"2011","journal-title":"Drug Metab. Rev."},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb1345","doi-asserted-by":"crossref","DOI":"10.1016\/j.phyplu.2022.100267","article-title":"In vitro demonstration of herbal exacerbation of paracetamol-induced hepatotoxicity","volume":"2","author":"Britza","year":"2022","journal-title":"Phytomed. Plus"},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb1350","article-title":"Nisha-Amalaki in uncontrolled type 2 diabetes mellitus - a case report","volume":"10","author":"Wale Savita","year":"2022","journal-title":"Int. J. Ayur. Pharma Res."},{"key":"10.1016\/j.lfs.2024.122806_bb1355","series-title":"Synergistic Behavior of Phytophenolics with Antidiabetic Drugs","author":"Hoda","year":"2019"},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb1360","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ijbiomac.2012.01.034","article-title":"Anti-diabetic activities of Acanthopanax senticosus polysaccharide (ASP) in combination with metformin","volume":"50","author":"Fu","year":"2012","journal-title":"Int. J. Biol. Macromol."},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb1365","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3390\/molecules27031106","article-title":"The therapeutic effect of Acanthopanax senticosus components on radiation-induced brain injury based on the pharmacokinetics and neurotransmitters","volume":"27","author":"Song","year":"2022","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.lfs.2024.122806_bb1370","article-title":"The effect of Berberis vulgaris extract on transaminase activities in non-alcoholic fatty liver disease","volume":"15","author":"Kashkooli","year":"2015","journal-title":"Hepat. Mon."},{"issue":"5","key":"10.1016\/j.lfs.2024.122806_bb1375","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s12272-014-0510-6","article-title":"Organic cation transporter-mediated drug-drug interaction potential between berberine and metformin","volume":"38","author":"Kwon","year":"2015","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.lfs.2024.122806_bb1380","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12272-011-0411-x","article-title":"Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin","volume":"34","author":"Choi","year":"2011","journal-title":"Arch. Pharm. Res."},{"issue":"3","key":"10.1016\/j.lfs.2024.122806_bb1385","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3390\/ijms23031044","article-title":"Quercetin reduces lipid accumulation in a cell model of NAFLD by inhibiting de novo fatty acid synthesis through the acetyl-CoA carboxylase 1\/AMPK\/PP2A axis","volume":"23","author":"Gnoni","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.lfs.2024.122806_bb1390","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.bcp.2008.01.010","article-title":"Quercetin pretreatment increases the bioavailability of pioglitazone in rats: involvement of CYP3A inhibition","volume":"75","author":"Umathe","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2024.122806_bb1395","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctim.2021.102699","article-title":"The effect of cinnamon supplementation on liver enzymes in adults: a systematic review and meta-analysis of randomized controlled trials","volume":"58","author":"Shekarchizadeh-Esfahani","year":"2021","journal-title":"Complement. Ther. Med."},{"issue":"1","key":"10.1016\/j.lfs.2024.122806_bb1400","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1574884712666170207152020","article-title":"Effect of Cinnamomum cassia on the pharmacokinetics and pharmacodynamics of pioglitazone","volume":"12","author":"Mamindla","year":"2017","journal-title":"Curr. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.lfs.2024.122806_bb1405","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/17425255.2021.1867105","article-title":"Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapy","volume":"17","author":"Bechtold","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.lfs.2024.122806_bb1410","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154925","article-title":"Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease","volume":"126","author":"Negi","year":"2022","journal-title":"Metabolism"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524003965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524003965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T11:04:07Z","timestamp":1725879847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320524003965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":282,"alternative-id":["S0024320524003965"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2024.122806","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unravelling the complexities of non-alcoholic steatohepatitis: The role of metabolism, transporters, and herb-drug interactions","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2024.122806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"122806"}}